For research use only. Not for therapeutic Use.
RMC-6236(Cat No.:I042471)is a novel, selective inhibitor of the mitogen-activated protein kinase (MAPK) pathway, specifically targeting the MEK1/2 enzymes. This pathway plays a crucial role in cell growth, survival, and differentiation, and its dysregulation is commonly associated with various cancers. By inhibiting MEK1/2, RMC-6236 aims to block abnormal cell proliferation and tumor growth, offering potential therapeutic benefits in cancers driven by this pathway, such as melanoma and other solid tumors. Ongoing research is focused on evaluating its efficacy, safety, and potential as a treatment option for patients with MAPK pathway-driven malignancies.
CAS Number | 2765081-21-6 |
Synonyms | (1S,2S)-N-[(7S,13S)-21-ethyl-20-[2-[(1S)-1-methoxyethyl]-5-(4-methylpiperazin-1-yl)pyridin-3-yl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,27,28-tetrazapentacyclo[17.5.2.12,5.19,13.022,26]octacosa-1(25),2,5(28),19,22(26),23-hexaen-7-yl]-2-methylcyclopropane-1-carboxamide |
Molecular Formula | C44H58N8O5S |
Purity | ≥95% |
IUPAC Name | (1S,2S)-N-[(7S,13S)-21-ethyl-20-[2-[(1S)-1-methoxyethyl]-5-(4-methylpiperazin-1-yl)pyridin-3-yl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,27,28-tetrazapentacyclo[17.5.2.12,5.19,13.022,26]octacosa-1(25),2,5(28),19,22(26),23-hexaen-7-yl]-2-methylcyclopropane-1-carboxamide |
InChI | InChI=1S/C44H58N8O5S/c1-8-51-37-12-11-28-19-31(37)33(40(51)32-20-29(23-45-39(32)27(3)56-7)50-16-14-49(6)15-17-50)22-44(4,5)25-57-43(55)34-10-9-13-52(48-34)42(54)35(21-38-46-36(28)24-58-38)47-41(53)30-18-26(30)2/h11-12,19-20,23-24,26-27,30,34-35,48H,8-10,13-18,21-22,25H2,1-7H3,(H,47,53)/t26-,27-,30-,34-,35-/m0/s1 |
InChIKey | FVICRBSEYSHKFY-JYQNNKODSA-N |
SMILES | CCN1C2=C3C=C(C=C2)C4=CSC(=N4)C[C@@H](C(=O)N5CCC[C@H](N5)C(=O)OCC(CC3=C1C6=C(N=CC(=C6)N7CCN(CC7)C)[C@H](C)OC)(C)C)NC(=O)[C@H]8C[C@@H]8C |